PEGylated fibrinogen-based biomatrix

• US 7,442,397 B2
• Filed: 06/23/2004
• Issued: 10/28/2008
• Est. Priority Date: 05/02/2002
• Status: Expired due to Term

• Current Assignee: Regents of The University of Minnesota (University of Minnesota)
• Original Assignee: Regents of The University of Minnesota (University of Minnesota)
• Inventors: Zhang, Jianyi
• Primary Examiner(s): BELYAVSKYI, MICHAIL A
• Application Number:
  US10/874,449
• Publication Number:
  US 20050118144A1
• Time in Patent Office: 1,588 Days
• Field of Search: None
• US Class Current: 426/577
• CPC Class Codes: A61L 24/0005 Ingredients of undetermined constitution or reaction products thereof
• CPC Class Codes: A61L 24/106 Fibrin; Fibrinogen
• CPC Class Codes: A61L 27/225 Fibrin; Fibrinogen
• CPC Class Codes: A61L 27/3804 characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
• CPC Class Codes: A61L 27/3869 Epithelial tissues other than skin
• CPC Class Codes: A61L 27/3873 Muscle tissue, e.g. sphincter
• CPC Class Codes: A61L 27/3895 using specific culture conditions, e.g. stimulating differentiation of stem cells, pulsatile flow conditions
• CPC Class Codes: A61L 27/50 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: C12N 2500/25 Insulin-transferrin; Insulin-transferrin-selenium
• CPC Class Codes: C12N 2501/11 Epidermal growth factor [EGF]
• CPC Class Codes: C12N 2501/135 Platelet-derived growth factor [PDGF]
• CPC Class Codes: C12N 5/0663 Bone marrow mesenchymal stem cells (BM-MSC)

Abstract

The invention involves methods and materials related to fibrin-based biomatrices.

Claims

1. A method of delivering stem or progenitor cells to infracted myocardial tissue of a mammal comprising depositing, onto or in the vicinity of a surface of said infracted myocardial tissue of said mammal, a PEGylated fibrinogen solution comprising said cells and at least one growth factor, wherein said growth factor is covalently bound to said PEG.

2. The method of claim 1, wherein said stem or progenitor cells are bone marrow cells.

3. The method of claim 2, wherein said bone marrow cells are autologous to said mammal.

4. The method of claim 1, wherein fibrinogen in said PEGylated fibrinogen solution is autologous to said mammal.

5. The method of claim 1, further comprising introducing a fibrinogen-converting agent to said PEGylated fibrinogen solution.

6. The method of claim 5, wherein said fibrinogen-converting agent is a serine protease.

7. The method of claim 6, wherein said serine protease is thrombin.

8. The method of claim 7, wherein said thrombin is autologous to said mammal.

9. The method of claim 5, wherein said fibrinogen-converting agent is added to said PEGylated fibrinogen solution before said depositing.

10. The method of claim 5, wherein said fibrinogen-converting agent is added to said PEGylated fibrinogen solution after said depositing.